Protocolo diabetes mellitus tipo 2 - Sociedad Española de Diabetes

FMC – Protocolos
35. The DECODE study group. Will new diagnostic criteria for
diabetes mellitus change phenotype of patients with diabetes
Reanalysis of european epidemiological data. BMJ
1998; 317: 371-375.
36. The DECODE study group. Glucose tolerance and mortality:
comparison of WHO and american diabetes association
diagnostic criteria. Lancet 1999; 354: 617-621.
37. The DECODE study group. Consequences of the new diagnostic
criteria for diabetes in older men and women. Diabetes
care 1999; 22: 1667-1671.
38. The Funagata diabetes Study. Impaired glucose tolerance is
a risk factor ford cardiovascular disease, but not impaired
fasting glucose. Diabetes care 1999; 22: 920-924.
39. Tuomi T, Carlsson A, Li H, Isimaa B, Miettinen A, Nissen
M. Clinical and genetic characteristics of type 2 diabetes
with and without GAD antibodies. Diabetes 1999; 48: 150-
157.
40. Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren
G. Antibodies to glutamic acid decarboxylase as predictors
of insulin-dependent diabetes mellitus before clinical onset
of disease. Lancet 1994; 343: 1383-1385.
41. Wahl PW, Savage PJ, Psatsy BM, Orchard TJ, Robbins JA,
Tracy RP. Diabetes in older adults: comparison of 1997
American Diabetes Association classification of diabetes
mellitus with WHO classification. Lancet 1998; 352: 1012-
1015.
42. Zimmet P, Tuomi T, Mackay IR, Rowley MJ, Knowles W.
Latent Autoimmune Diabetes Mellitus in Adults (LADA):
the role of antibodies to glutamic acid decarboxylase in
diagnosis and prediction of insulin dependency. Diabetic
Med 1994; 11: 299-303.
Alimentación
43. American Diabetes Association. Nutrition recommendations
and principles for people with diabetes mellitus. Diabetes
Care 2000; 23 (Supl 1): 43-46.
44. Cervera P. Alimentación y dietoterapia. (3. a ed.). Madrid:
Editorial Interamericana 1999.
45. Close EJ, Wiles PG, Lockton JA, Walnsley D, Oldham J,
Wales JK. Diabetic diets and nutritional recomendations:
what happens in real life. Diabetic Med 1992; 9: 181-188.
46. Elena M, Pérez M, Jansa M, Deulofeu R, Esmatjes E,
Schinca N et al. Contenido en hidratos de carbono y oligoelementos
de un grupo de bebidas refrescantes no alcohólicas.
Med Clin (Barc) 1998; 110: 365-369.
47. Facchini F, Chen YDI, Reaven GH. Light-to-moderate alcohol
intake is associated with enhaced insulin sensitivity.
Diabetes Care 1994; 17: 115-119.
48. Garg A. High-monoinsaturated fat diet for diabetic patinets.
Diabetes Care 1994; 17: 242-246.
49. Nuttall FQ, Chasuk RM. Nutrition and the manegement of
type 2 Diabetes. J Fam Pract 1998; 47 (Supl): 45-53.
50. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R,
Bergman RN. Caloric restriction per se is a significant factor
in improvements in glycemic control and insulin sensitivity
during weight loss in obese NIDDM patients. Diabetes
Care 1994; 17: 30-36.
Ejercicio
51. American Diabetes Association. Position statement: diabetes
mellitus and exercise. Diabetes Care 2000; 23 (Supl 1): 50-54.
52. American College of Sports Medicine. Guidelines for
Exercise Testing and Prescription, (5ª ed.). Baltimore: Williams
and Wilkins, 1995.
53. Ortega R. Medicina del ejercicio físico y del deporte para
la atención de la salud. Madrid: Díaz de Santos, 1992.
54. Ortega R, Pujol P. Estilos de vida saludables: actividad física.
Barcelona: Ergón, 1997.
Tratamiento farmacológico
55. American Diabetes Association. Consensus statement: the
pharmacological treatment of hyperglycemia in NIDDM
Diabetes Care 1995; 18: 1510-1518.
56. Abraira C, Colwell JA, Nuttall F, Sawin C, Johnson-Nagel
N, Comstock J et al. Veterans administration Cooperative
Study on glycemic control and complications in type 2 diabetes:
results of the feasibility trial. Diabetes Care 1995;
18: 1113-1123.
57. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin
in patients with poorly controlled, insulin-treated type 2
diabetes mellitus. A randomized, double-blind, placebocontrolled
trial. Ann Intern Med 1999; 131: 182-188.
58. Bailey CJ. Metformin. N Engl J Med 1996; 334: 574-578.
59. Chiasson JL, Joss RG, Hunt JA, Palmason C, Rodger NW,
Ross SA et al. The efficacy of acarbose in the treatment of
patients with non-insulin-dependent diabetes mellitus. A multicenter
controlled trial. Ann Intern Med 1994; 121: 928-935.
60. De Fronzo RA. Pharmacological therapy for type 2 diabetes
mellitus. Ann Intern Med 1999; 131: 281-303.
61. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13:
1240-1264.
62. Hermann LS, Schersten B, Bitzen PO, Kjellström T,
Lindgärde F, Melander A. Therapeutic comparison of metformin
and sulfonylurea, alone and in various combinations.
Diabetes Care 1994; 17: 1100-1109.
63. Holman RR, Turner RC, Cull CA, on behalf of the UKPDS
Study Group. A randomized double-blind trial of Acarbose
in type 2 diabetes shows improved glycemic control over 3
years (UK Prospective Diabetes Study 44). Diabetes Care
1999; 22: 960-964.
64. Imura H. A novel antidiabetic drug, troglitazone: reason for
hope and concern. N Engl J Med 1998; 338: 908-909.
65. Johansen K. Efficacy of metformin in the treatment of
NIDDM. Meta-analysis. Diabetes Care 1999; 22: 33-37.
66. Johnson J, Wolf S, Kabadi U. Efficacy of insulin and sulfonylurea
combination therapy in type 2 diabetes. A metaanalysis
of the randomized placebo-controlled trials. Arch
Intern Med 1996; 156: 259-264.
67. Lebovitz HE. Insulin secretagogues: old and new. Diabetes
Rev 1999; 7: 139-153.
68. Lindström MJ, Eriksson P, Olsson A, Arnqvist H. Longterm
improvement of glycemic control by insulin treatment
in NIDDM patients with secondary failure of sulfonilueres.
Diabetes Care 1994; 17: 719-721.
69. Owens DR. Repaglinide-prandial glucose regulator: a new
class of oral antidiabetic drugs. Diabet Med 1998; 15 (Supl
4): 28-36.
70. Plosker GL, Faulds D. Troglitazone: a review of its use in
the mangement of type 2 diabetes mellitus. Drugs 1999;
57: 409-438.
71. Turner RC, Cull CA, Frighi V, Holman RR, for the UK
Prospective Diabetes Study (UKPDS) Group. Glycemic
control with diet, sulfonylurea, metformin or insulin in patients
with type 2 diabetes mellitus. Progressive requirement
for multiple therapies (UKPDS 49). JAMA 1999;
281: 2005-2012.
72. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen
T, Niskanen L et al. Comparison of insulin regimens in
51